We have attempted to model human metastatic disease by implanting human target organs into the immunodeficient C.B-17 scid/scid (severe combined immunodeficiency; SCID) mouse, creating SCID-hu 
variant SCLC to human fetal bone marrow was enhanced in SCID-hu mice exposed to y-irradiation or to interleukin la. These data indicate that the SCID-hu mice may provide a model in which to study species-and tissue-specific steps of the human metastatic process.
Research on tumor metastasis relies heavily on the availability of experimental in vivo metastasis models. However, understanding of-the mechanisms of metastasis of human tumors has been hampered by the fact that many malignant human tumors are poorly tumorigenic and/or metastatic after inoculation into immunodeficient rodents (1, 2) . The introduction of orthotopic implantation of human tumor cells into homologous mouse organs has significantly improved the outcome of metastasis assays (3) (4) (5) (6) . However, some human tumors apparently require a specific human tissue microenvironment to reproduce their clinical growth and invasion patterns in experimental in vivo models. Thus, growth of primary human T-cell lymphomas is greatly enhanced in human lymphoid microenvironment in severe combined immunodeficiency mice engrafted with human tissue (SCID-hu mice) (7) . Primary human myeloid leukemias grow selectively within the human bone marrow implanted in SCID mice (8) . Human melanoma cells faithfully reproduce the clinical patterns of growth and invasion only when injected into human skin grafts implanted in SCID mice (9) .
The tissue-specificity of metastases associated with different human malignancies has been difficult to reproduce in the existing in vivo metastasis models. The majority of human tumor cells that demonstrate metastatic behavior in mouse models usually generate pulmonary metastatic lesions. We hypothesized that the lack of metastases or lack of the tissuespecificity of metastasis of malignant human cells in immunodeficient rodents might be, at least in part, due to the possibility that the mechanisms governing the establishment of tissue-specific metastases are also species-specific. As a consequence, experimental metastasis models that involve passage of malignant human cells into immunodeficient rodents may either fail to detect metastatic potential or, alternatively, select for the nonrepresentative outgrowth of human cell variants that can interact with murine organ microenvironments.
We set out to test the hypothesis that certain human tumor cells that are unable to lodge and/or grow in mouse organs, and thus are scored as negative in existing experimental metastasis models, might prove to be metastatic to human organs implanted within the SCID mouse (10, 11) . To (Fig. 1 B-D) . Engraftment of SCID mice with HFBM (SCID-hu-BM) was described in detail (15 (Fig. 1D) However, selection of variants of N417 metastatic to HFBM was not associated with a significant increase in frequency of metastases to mouse bone marrow (Table 2) . Metastatic lesions in mouse vertebral bone marrow were usually limited to one vertebra and were small enough to remain confined to the medullar space. This result suggests that metastasis to and growth of human SCLC in the mouse bone marrow can occur but not as efficiently as in HFBM.
To exclude the possibility that metastasis of SCLC to HFBM is an artifact of engraftment, SCID mice were engrafted with bones from newborn SCID mice. The bone fragments implanted into mammary fat pads showed the presence of morphologically normal marrow within 4 weeks after implantation (data not shown). Cells of N4BM4, a cell line established after four rounds of selection in vivo for variants metastatic to HFBM, were injected into SCID mice engrafted with exogenous SCID bone marrow. None of the nine injected mice developed metastases to the SCID bone marrow grafts, even at 8 weeks after injection. This result further confirms the species-specific nature of bone marrow metastases of SCLC.
Effect of y-Radiation and IL-la on Metastasis of v-SCLC to Late HFBM. We addressed the possible reasons for the observed specificity of metastasis of v-SCLC to HFBM at early postimplantation times. We hypothesized that the abundant bone marrow stroma in early HFBM may actively produce cytokines and/or express specific adhesion molecules necessary to support the ensuing human hematopoiesis, thus creating favorable conditions for the homing and/or proliferation of metastatic cells. We tried to induce similar conditions in the late HFBM implants by subjecting SCID-hu-BM to sublethal doses of y-irradiation. Sublethal irradiation of SCID-hu-BM results in massive death of hematopoietic cells in the HFBM followed by recovery (19) , similar to the events observed in HFBM grafts after implantation (15) .
SCID-hu-BM at 8-10 weeks after implantation were subjected to sublethal whole-body irradiation before injection of N4BM4 cells. Results in Table 3 show that irradiation at 1 or 3, but not 7 days, before injection results in metastasis of N4BM4 cells to late HFBM, whereas control unirradiated mice did not develop tumors in HFBM. Irradiation had no effect on metastasis to mouse bone marrow (Table 3) or to mouse brown fat (data not shown). Irradiation of SCID-hu-BM before injection of the parental N417 cells did not result in the increased frequency of metastasis to HFBM (Table 3) . We conclude that sublethal irradiation activates a temporary response in late HFBM grafts that augments the species-specific metastasis of SCLC variants.
To ascertain that the effect of irradiation on metastasis to HFBM is not due to the damage and the loss of integrity of the endothelial barrier, experimental mice were treated with cyclophosphamide, an agent known to induce morphological changes in bone marrow endothelium similar to those induced by irradiation (20, 21) . None of these mice has developed metastases in HFBM grafts upon subsequent injection with N4BM4 cells or the parental line N417 (Table 3) . Thus Table 3 , a dramatic increase in species-specific metastasis to late HFBM was observed in SCID-hu-BM that were injected with IL-la 
